Literature DB >> 35882818

Taurine-Derived Compounds Produce Anxiolytic Effects in Rats Following Developmental Lead Exposure.

Lorenz S Neuwirth1,2, Bright U Emenike3, George B Cruz4,5, Ericka Cabañas4,5, Michelle A Vasquez4,3, Jewel N Joseph4,5, Zaid Ayaz4,5, Mohammed Mian4,5, Mohamed M Ali4,5, Evan G Clarke4,5, Eddy D Barrera6,4, Nimra Hameed4,5, Samantha Rubi4,5, Teddy F Dacius6,4, Jourvonn C Skeen4,5, Jalen R Bonitto4,5, Eric B Khairi4,5, Asma Iqbal6,4, Isra Ahmed6,4, Tokunbo J Jose6,4, Kirsten P Lynch6,4, Amber Alivira6,4, Neena Mathew6,4, Sukhpreet Kaur6,4, Sidrah Masood6,4, Bettina Tranquilee4,5, Veni Thiruverkadu4,5.   

Abstract

Lead (Pb2+) is a developmental neurotoxicant that disrupts the GABA-shift and subsequently causes alterations in the brain's excitation-to-inhibition (E/I) balance. Taurine is a well-established neuroprotective and inhibitory compound for regulating brain excitability. Since mechanistically taurine can facilitate neuronal inhibition through the GABA-AR, the present study examined the anxiolytic potential of taurine derivatives. Treatment groups consisted of the following developmental Pb2+-exposures: Control (0 ppm) and Perinatal (150 ppm or 1,000 ppm lead acetate in the drinking water). Rats were scheduled for behavioral tests between postnatal days (PND) 36-45 with random drug assignments to either saline, taurine, or taurine-derived compound (TD-101, TD-102, or TD-103) to assess the rats' responsivity to each drug in mitigating the developmental Pb2+-exposure and anxiety-like behaviors through the GABAergic system. Long-Evans hooded rats were assessed using an open field (OF) test for preliminary locomotor assessment. Twenty-four hours later, the same rats were exposed to the elevated plus maze (EPM) and were given an i.p. injection of 43 mg/Kg of the saline, taurine, or TD drugs 15 min prior to testing. Each rat was tested using the triple-blind random assignment method for each drug condition. The OF data revealed that Control female rats had increased locomotor activity over Control male rats, and the Pb2+-exposed males and females had increased locomotor activity when compared to the Control male and female rats. However, in the EPM, the Control female rats exhibited more anxiety-like behaviors over Control male rats, and the Pb2+-exposed male and female rats showed selective responsivity to TD drugs when compared to taurine. For Pb2+-exposed males, TD-101 showed consistent recovery of anxiety-like behaviors similar to that of taurine regardless of Pb2+ dose, whereas in Pb2+-exposed females TD-101 and TD-103 showed greater anxiolytic responses in the EPM. The results from the present psychopharmacological study suggests that taurine and its derivatives are interesting drug candidates to explore sex-specific mechanisms and actions of taurine and the associated GABAergic receptor properties by which these compounds alleviate anxiety as a potential behavioral pharmacotherapy for neurodevelopmental Pb2+ exposure.
© 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  Anxiety-like behaviors; Anxiolytic drugs; Developmental lead (Pb2+) exposure; GABAergic system; Lead poisoning; Taurine derivatives

Mesh:

Substances:

Year:  2022        PMID: 35882818     DOI: 10.1007/978-3-030-93337-1_42

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   3.650


  68 in total

1.  Intellectual impairment in children with blood lead concentrations below 10 microg per deciliter.

Authors:  Richard L Canfield; Charles R Henderson; Deborah A Cory-Slechta; Christopher Cox; Todd A Jusko; Bruce P Lanphear
Journal:  N Engl J Med       Date:  2003-04-17       Impact factor: 91.245

2.  Intellectual impairment and blood lead levels.

Authors:  David C Bellinger; Herbert L Needleman
Journal:  N Engl J Med       Date:  2003-07-31       Impact factor: 91.245

Review 3.  The GABA excitatory/inhibitory shift in brain maturation and neurological disorders.

Authors:  Yehezkel Ben-Ari; Ilgam Khalilov; Kristopher T Kahle; Enrico Cherubini
Journal:  Neuroscientist       Date:  2012-04-30       Impact factor: 7.519

Review 4.  Very low lead exposures and children's neurodevelopment.

Authors:  David C Bellinger
Journal:  Curr Opin Pediatr       Date:  2008-04       Impact factor: 2.856

Review 5.  Low-level lead exposure and cognitive function in children.

Authors:  D Bellinger; K N Dietrich
Journal:  Pediatr Ann       Date:  1994-11       Impact factor: 1.132

6.  Differential contribution of current and cumulative indices of lead dose to neuropsychological performance by age.

Authors:  M L Bleecker; K N Lindgren; D P Ford
Journal:  Neurology       Date:  1997-03       Impact factor: 9.910

7.  Taurine, taurine analogues, and taurine functions: overview.

Authors:  L Bianchi; M A Colivicchi; C Ballini; M Fattori; C Venturi; M G Giovannini; J Healy; K F Tipton; L Della Corte
Journal:  Adv Exp Med Biol       Date:  2006       Impact factor: 2.622

8.  Low-level lead exposure, intelligence and academic achievement: a long-term follow-up study.

Authors:  D C Bellinger; K M Stiles; H L Needleman
Journal:  Pediatrics       Date:  1992-12       Impact factor: 7.124

Review 9.  Developmental neurotoxicants in e-waste: an emerging health concern.

Authors:  Aimin Chen; Kim N Dietrich; Xia Huo; Shuk-mei Ho
Journal:  Environ Health Perspect       Date:  2010-11-15       Impact factor: 9.031

Review 10.  A critical review of biomarkers used for monitoring human exposure to lead: advantages, limitations, and future needs.

Authors:  Fernando Barbosa; José Eduardo Tanus-Santos; Raquel Fernanda Gerlach; Patrick J Parsons
Journal:  Environ Health Perspect       Date:  2005-12       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.